A Joe Mikhael Icebreaker Fulfilled
Dr. Gotlib talks about fulfilling a lifelong dream of spending time with sloths by visiting Kids Saving the RainForest while on a recent trip to Costa Rica.
Another Therapeutic Agent in the Pipeline for Preventing Acute Vaso-Occlusive Events in Sickle Cell Disease
Dr. DeBaun looks at experiments using ARQ 092 as a possible therapeutic agent for preventing acute vaso-occlusive events in sickle cell disease.
A concise review of a topic that illustrates the relationship of basic research to clinical hematology
Drs. Sojitra, Arber, and George cover the 2017 joint guidelines from ASH and the College of American Pathologists on testing for the initial workup of acute leukemia.
Dr. Hoggatt discusses stem cell transplantation and looks at new, targeted conditioning approaches that have recently emerged, where the potential patient pool could be remarkably expanded with the advent of new gene therapy and editing strategies.
Dr. George and Dr. Czuchlewski cover the World Health Organization's 2016 updates to the classification of myeloid neoplasms.
Dr. Garcia highlights clinical recommendations from the ACCP's evidence-based guidelines for the treatment of venous thromboembolism (VTE) that are most relevant to hematologists.
Dr. Yang and Dr. Press evaluate the clinical utility of next-generation DNA sequencing (NGS) methods to profile the multiple actionable driver genes in patients with known and/or suspected myeloid malignancies.
Drs. Yao, Cardó-Vila, Ahmadian, Ebaid, Arap, and Pasqualini discuss the existence of tumor-specific molecular zip codes that can be used to design drugs to treat leukemia, lymphoma, and solid tumors.
Drs. Oh and Fisher discuss the application of mass cytometry to analyze disease evolution in hematologic malignancies.
Dr. Raje and Dr. Santo discuss new insights into MM-related bone biology and potential novel therapeutic approaches for treating bone disease.
Drs. Falet, Grozovsky, and Hoffmeister look at desialylated platelets to understand the steady state of hepatic TPO regulation and the mechanisms of thrombocytopenia observed in patients with MPNs treated with JAK1/2 inhibitors.
Dr. Cabantchik and Dr. Rachmilewitz talk about potential toxicity in Iron Overload Disorder caused by labile cell iron or labile iron pool.
May-June 2017Volume 14, Issue 3
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology